Size | Price | Stock | Qty |
---|---|---|---|
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
ln Vitro |
L-1210 cell growth is inhibited by chelerythrine (IC50: 0.53 uM) for 48 hours[1]. Chelerythrine (0–20 μM, 24 hours) can increase autophagy and self-healing in cells while suppressing the viability of A549 and NCI-H1299 cells. Chelerythrine (0–5 μM, 24 or 48 hours) can cause SH-SY5Y cells that overexpress BclXL. Death [3]. In SH-SY5Y cells, chelerythrine (2.5–10 μM, 16) can cause necrosis [4]. Chelidonine (0-100 ng/mL, 24 hours) decreases the production of NO and TNF-α in primary macrophages stimulated by LPS. Cheerythrine (MIC: 0.156 mg/mL) exhibits antibacterial activity against MRSA, extended-spectrum beta-lactamase Staphylococcus aureus (ESBLs-SA), and Gram-positive bacteria.
|
---|---|
ln Vivo |
Renal function can be restored and the renal damage caused by partial uniuretic ureteral obstruction (UUO) in neovascularization can be lessened with erythrine (5 mg/kg, intraperitoneal injection, daily) [2]. Increased nocturnal rate, decreased nitrite and TNF-α levels, as well as anti-inflammatory effects were observed in LPS-induced toxic shock after injections of chelerythrine (1–10 mg/kg, i.p.) and 100 μg/kg LPS (first 24 hours and 1 hour) [5].
|
Cell Assay |
Western Blot analysis [4]
Cell Types: A549 and NCI-H1299 Cell Tested Concentrations: 10, 15, 20 μM Incubation Duration: 24 h Experimental Results: The expression of LC3-II was induced in a beclin 1-dependent manner. |
Animal Protocol |
Animal/Disease Models: Unilateral ureteral obstruction (UUO)-induced neonatal rats [2]
Doses: 5 mg/kg Route of Administration: intraperitoneal (ip) injection, daily Experimental Results: diminished renal damage (increased kidney weight and restored renal function). Inhibits UUO-induced upregulation of renal injury molecule 1 expression, cell apoptosis and renal fibrosis. |
References |
[1]. Herbert JM, et al. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun. 1990 Nov 15;172(3):993-9.
[2]. Shi B, et al. Protein kinase C inhibitor chelerythrine attenuates partial unilateral ureteral obstruction induced kidney injury in neonatal rats. Life Sci. 2019 Jan 1;216:85-91. [3]. Chan SL, et al.Identification of chelerythrine as an inhibitor of BclXL function.J Biol Chem. 2003 Jun 6;278(23):20453-6. [4]. Tang ZH, et al.Induction of reactive oxygen species-stimulated distinctive autophagy by chelerythrine in non-small cell lung cancer cells.Redox Biol. 2017 Aug;12:367-376. [5]. Li W, et al. Effect of chelerythrine against endotoxic shock in mice and its modulation of inflammatory mediators in peritoneal macrophages through the modulation of mitogen-activated protein kinase (MAPK) pathway. Inflammation. 2012 Dec;35(6):1814-24. [6]. He N, et al. Antibacterial mechanism of chelerythrine isolated from root of Toddalia asiatica (Linn) Lam. BMC Complement Altern Med. 2018 Sep 26;18(1):261. |
Molecular Formula |
C21H18NO4
|
---|---|
Molecular Weight |
348.3719
|
CAS # |
34316-15-9
|
Related CAS # |
Chelerythrine chloride;3895-92-9
|
SMILES |
O1C([H])([H])OC2=C1C([H])=C1C(=C2[H])C([H])=C([H])C2=C3C([H])=C([H])C(=C(C3=C([H])[N+](C([H])([H])[H])=C21)OC([H])([H])[H])OC([H])([H])[H]
|
Synonyms |
Chelerythrine
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8705 mL | 14.3526 mL | 28.7051 mL | |
5 mM | 0.5741 mL | 2.8705 mL | 5.7410 mL | |
10 mM | 0.2871 mL | 1.4353 mL | 2.8705 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.